FDA alerts providers to recall of drug to treat serious bacterial infections
The Food and Drug Administration yesterday alerted pharmacy and nursing professionals to a voluntary recall of seven lots of an injectable drug used to treat certain serious bacterial infections, which may contain glass particulate matter. The Teva Pharmaceuticals Amikacin Sulfate Injection USP vials were distributed nationwide through wholesalers, retailers and pharmacies. Anyone with an existing inventory of the recalled lots should stop using and quarantine the product immediately, FDA said. Health care professionals and patients are encouraged to report adverse events or side effects related to the use of the product to the FDA's MedWatch program.
Related News Articles
Headline
There are 933 cases in the South Carolina measles outbreak, the state’s Department of Public Health reported Feb. 10. Of those, 859 cases are unvaccinated, 20…
Headline
The measles outbreak in South Carolina has increased to 876 cases, the state’s Department of Public Health reported Feb. 3. Last week, the South Carolina…
Headline
Thomas McGinn, M.D., senior executive vice president and chief physician executive officer at CommonSpirit Health, shares how the organization aligns…
Headline
The Centers for Disease Control and Prevention released its annual progress report on health care-associated infections Jan. 29, which found continued…
Headline
The South Carolina Department of Public Health announced Jan. 30 that the state’s measles outbreak now has 847 cases. The agency said most cases are close…
Headline
Two AHA guides offer strategies for hospitals and health systems in preparing for public health emergencies and disasters and managing cybersecurity incidents…